Publications found:
253,683
Sort by:
Medical Affairs Reputations (US) [RA]
US$ 6,175.00
... ? How well does your Rheumatoid Arthritis medical affairs team performance compare with the rest? Use Medical Affairs Reputations: Rheumatoid Arthritis 2017 (US) to discover how ...
September 2017
NPS+ (EU5) [Myeloma]
US$ 2,575.00
... does each of the leading brands compare to its competitors? NPS+ Multiple Myeloma (EU5) gives a unique insight into the overall brand health of 7 leading ... ) Explore Important Brand Loyalty Issues NPS+ Multiple Myeloma (EU5) gives you clear and independent insight into myeloma brand loyalty from the doctors ...
September 2017
NPS+ (US) [Myeloma]
US$ 2,575.00
... to US oncologists and haematologists to treat multiple myeloma. Clearly some of these options are achieving ... the leading brands compare to its competitors? NPS+ Multiple Myeloma (US) gives a unique insight into the ... Issues NPS+ Multiple Myeloma (US) gives you clear and independent insight into myeloma brand ...
September 2017
Prostate Cancer [2017]
US$ 8,145.00
... Zytiga or Xtandi? Is the jury still out on immunotherapies in prostate cancer? Do KOLs believe that vaccine-based therapies or PD-1/PD-L1 checkpoint inhibitors ... Honorary Consultant in Clinical Oncology and Prostate Cancer Translational Research at The Institute of Cancer Research and The Royal Marsden, London ...
September 2017
Riding the Wearable Trend: Opportunities for Pharma
US$ 695.00
Riding the Wearables Trend: Opportunities for Pharma Wearable health technology ... potential? Riding the Wearables Trend: Opportunities for Pharma investigates the potential for wearable devices, ... the expertise of outsiders to successfully adapt to the wearable trend, or create new internal roles and functions? ...
September 2017
The Future of Market Access in Europe
US$ 2,245.00
... price harmonisation Will Brexit disrupt EU market access to medicines? Evolving market-access challenges and remedies in Europe ... market access Where market-access policies are heading at national level Key insights Variation and consistency in market-access factors at national level Traditional market-access ...
September 2017
The Future of Market Access in US
US$ 2,245.00
... nature of FDA not viewed as a hindrance to market access Drugmaker response and market access Key insights RWD could prove helpful in making formulary ... not expected to alter market access The US political climate and market access Key insights Obamacare has had mixed impact on market access, but repeal brings ...
September 2017
Value Added Services in Cardiometabolic Diseases -- Payer views
US$ 2,245.00
... value-added services? The role of value-added services in cardiometabolic diseases Key insights on the role of value-added services in cardiometabolic diseases The challenge of behavioural change Do VAS influence pricing & reimbursement decisions? Types of value-added services ...
September 2017
Harnessing Patient-Centricity to Drive Profitability
US$ 695.00
... success look like? And can patient-centric performance be accurately measured or compared? Harnessing Patient Centricity to Drive Profitability takes a pragmatic view across the patient-centric landscape, drawing upon the ...
September 2017
Innovative drugs: Mapping the pricing, reimbursement and HTA landscape
US$ 695.00
... set, this ground breaking analysis exposes the pricing, reimbursement and HTA review status of innovative drugs in Australia, Canada, France, Germany and the ... the pricing, reimbursement and HTA status of each product at the national level Profile the therapy areas that are being targeted by innovative drugs ...
September 2017
SPMS- Disease Overview
US$ 1,000.00
Detailed overview of SPMS disease area including its definition, etiology, symptoms and disease diagnosis
September 2017
18 pages
SPMS- Disease Overview and Epidemiology
US$ 2,000.00
Overview of Secondary progressive multiple sclerosis disease indication in detail and SPMS epidemiology in the present scenario and in future (forecasted) as well in the key geographies across the globe.
September 2017
26 pages
SPMS- Disease Overview, Epidemiology and Drug Overview
US$ 3,000.00
Report gives the overview of Secondary progressive multiple sclerosis disease indication in detail, highlights the SPMS epidemiology in the present scenario and in future (forecasted) as well in the ... globe and elaborates on the drugs prescribed and expected to be prescribed in SPMS by the physicians.
September 2017
65 pages
SPMS- A Detailed Overview
US$ 5,000.00
The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail, highlights the SPMS epidemiology in the key geographies, elaborates on ... the drugs prescribed and expected to be prescribed in SPMS and covers the detailed market sizing drug wise and country wise in value ...
September 2017
110 pages
PPMS- Disease Overview
US$ 1,000.00
Detailed overview of PPMS disease area including its definition, etiology, symptoms and disease diagnosis
September 2017
20 pages
PPMS- Disease Overview and Epidemiology
US$ 2,000.00
Overview of Primary progressive multiple sclerosis disease indication in detail and PPMS epidemiology in the present scenario and in future (forecasted) as well in the key geographies across the globe.
September 2017
27 pages
PPMS- Disease Overview, Epidemiology and Drug Overview
US$ 3,000.00
Report gives the overview of Primary progressive multiple sclerosis disease indication in detail, highlights the PPMS epidemiology in the present scenario and in future (forecasted) as well in the ... globe and elaborates on the drugs prescribed and expected to be prescribed in PPMS by the physicians.
September 2017
62 pages
PPMS- A Detailed Overview
US$ 5,000.00
The report gives the overview of Primary progressive multiple sclerosis disease indication in detail, highlights the PPMS epidemiology in the key geographies, elaborates on ... the drugs prescribed and expected to be prescribed in PPMS and covers the detailed market sizing drug wise and country wise in value ...
September 2017
103 pages
PPMS- France Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in France market, highlights the PPMS epidemiology in France, elaborates on ... final part of the report gives a detailed overview of PPMS market sizing drug wise in France both in terms of value sales and patient ...
September 2017
73 pages
PPMS- Germany Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in Germany market, highlights the PPMS epidemiology in Germany, elaborates on ... final part of the report gives a detailed overview of PPMS market sizing drug wise in Germany both in terms of value sales and patient ...
September 2017
73 pages
PPMS- Italy Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in Italy market, highlights the PPMS epidemiology in Italy, elaborates on ... The final part of the report gives a detailed overview of PPMS market sizing drug wise in Italy both in terms of value sales and patient ...
September 2017
73 pages
PPMS- Spain Overview
US$ 3,000.00
... report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in Spain market, highlights the PPMS epidemiology in Spain, elaborates on ... The final part of the report gives a detailed overview of PPMS market sizing drug wise in Spain both in terms of value sales and patient ...
September 2017
73 pages
PPMS- UK Overview
US$ 3,000.00
... . The report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in UK market, highlights the PPMS epidemiology in UK, elaborates on ... forms of MS. The final part of the report gives a detailed overview of PPMS market sizing drug wise in UK both in terms of value sales ...
September 2017
73 pages
PPMS- US Overview
US$ 3,000.00
... The report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in the US market, highlights the PPMS epidemiology in the US, ... progressive forms of MS. The final part of the report gives a detailed overview of PPMS market sizing drug wise in the US both in terms of value ...
September 2017
73 pages
SPMS- France Overview
US$ 3,000.00
... report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in France market, highlights the SPMS epidemiology in France, elaborates on ... final part of the report gives a detailed overview of SPMS market sizing drug wise in France both in terms of value sales and patient ...
September 2017
78 pages
SPMS- Germany Overview
US$ 3,000.00
... gives the overview of Secondary progressive multiple sclerosis disease indication in detail in Germany market, highlights the SPMS epidemiology in Germany, elaborates on ... final part of the report gives a detailed overview of SPMS market sizing drug wise in Germany both in terms of value sales and patient ...
September 2017
78 pages
SPMS- Italy Overview
US$ 3,000.00
... report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in Italy market, highlights the SPMS epidemiology in Italy, elaborates on ... The final part of the report gives a detailed overview of SPMS market sizing drug wise in Italy both in terms of value sales and patient ...
September 2017
78 pages
SPMS- Spain Overview
US$ 3,000.00
... report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in Spain market, highlights the SPMS epidemiology in Spain, elaborates on ... The final part of the report gives a detailed overview of SPMS market sizing drug wise in Spain both in terms of value sales and patient ...
September 2017
78 pages
SPMS- UK Overview
US$ 3,000.00
... . The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in UK market, highlights the SPMS epidemiology in UK, elaborates on ... forms of MS. The final part of the report gives a detailed overview of SPMS market sizing drug wise in UK both in terms of value sales ...
September 2017
78 pages
SPMS- US Overview
US$ 3,000.00
... The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail in the US market, highlights the SPMS epidemiology in the US, ... progressive forms of MS. The final part of the report gives a detailed overview of SPMS market sizing drug wise in the US both in terms of value ...
September 2017
78 pages
Major Depressive Disorder (Mdd) - Market Outlook, Market Forecast And Competitve Landscape Report - 20185 To 2030
US$ 5,000.00
Thelansis Knowledge Partners 'Major Depressive Disorder (MDD)' - Market Outlook, Market Forecast ... , Prevalence and mortality) and forecasted trend for 8 major markets (US, Germany, France, Italy, Spain, UK, ... Phase I, Phase II and Phase III including their major milestones, study result, interim result, safety & ...
September 2017
257 pages
Human Papillomavirus (Hpv) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Human Papillomavirus (HPV)' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – ... profile and probable launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, Base case, Low) of the ...
September 2017
216 pages
Uveitis - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Uveitis' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report ... , competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement scenario; Public, Private, Medicare, ...
September 2017
204 pages
Cutaneous T-Cell Lymphoma(Ctcl) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Cutaneous T-Cell Lymphoma(CTCL)' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – ... profile and probable launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, Base case, Low) of ...
September 2017
195 pages
Interstitial Cystitis - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Interstitial Cystitis' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
September 2017
208 pages
H3N2 Infection - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'H3N2 Infection' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
September 2017
147 pages
Helicobacter Pylori Infections - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Helicobacter Pylori Infections' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – ... profile and probable launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, Base case, Low) of ...
September 2017
217 pages
Hemophilia B - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Hemophilia B' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report ... emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
September 2017
158 pages
Hepatic Encephalopathy - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Hepatic Encephalopathy' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
September 2017
190 pages
Hepatitis A - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Hepatitis A' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report ... emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
September 2017
199 pages
Herpes Labialis - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Herpes Labialis' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
September 2017
158 pages
